Recent News

• 09.10.2025 - PMV Pharmaceuticals Investor Webinar to Review Phase 2 PYNNACLE Interim Data Evaluating Rezatapopt in Patients with Advanced Solid Tumors
• 09.10.2025 - PMV Pharmaceuticals Investor Webinar to Review Phase 2 PYNNACLE Interim Data Evaluating Rezatapopt in Patients with Advanced Solid Tumors
• 09.10.2025 - PMV Pharmaceuticals Announces Promising Rezatapopt Monotherapy Interim Data From PYNNACLE Phase 2 Trial Across Multiple Solid Tumors With a TP53 Y220C Mutation
• 09.10.2025 - PMV Pharmaceuticals Announces Promising Rezatapopt Monotherapy Interim Data From PYNNACLE Phase 2 Trial Across Multiple Solid Tumors With a TP53 Y220C Mutation
• 08.07.2025 - PMV Pharmaceuticals Reports Second Quarter 2025 Financial Results and Corporate Highlights
• 08.07.2025 - PMV Pharmaceuticals Reports Second Quarter 2025 Financial Results and Corporate Highlights

Recent Filings

• 08.14.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 08.13.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 08.07.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 08.07.2025 - EX-99.1 EX-99.1
• 08.07.2025 - 8-K Current report
• 07.03.2025 - 4 Statement of changes in beneficial ownership of securities
• 07.03.2025 - 4 Statement of changes in beneficial ownership of securities
• 07.03.2025 - 4 Statement of changes in beneficial ownership of securities
• 07.03.2025 - 4 Statement of changes in beneficial ownership of securities
• 06.09.2025 - 4 Statement of changes in beneficial ownership of securities